Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The overall objective of this study is to continue to improve the cure rate of childhood acute lymphoblastic leukemia (ALL) in Singapore and Malaysia in the context of a multi-centre cooperative trial using a risk-stratified therapy based primarily on early response to therapy utilizing a simplified minimal residual disease (MRD-lite) platform.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National University Hospital, Singapore
• Treatments: 6-Mercaptopurine; Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Doxorubicin; Fludarabine; Mercaptopurine; Methotrexate; Prednisolone; Thioguanine; Vincristine

Criteria

Inclusion Criteria:

1. Confirmed diagnosis of non-Burkitt B-lineage ALL

2. 1 to 17 years of age (before 18th birthday)

3. Renal function within normal range for age

4. Liver function within normal range for age

5. Able to participate in the full 2 years of treatment

Exclusion Criteria:

1. Age less than one year or age greater than/equals to 18 years

2. Previous treatment with cytotoxic agents or high-dose steroids

3. Mixed phenotype acute leukemia (MPAL)

4. ALL as secondary malignancy

5. Abnormal renal or liver function

6. Doubtful compliance or unable to afford full course of therapy